Nanatinostat is a Small Molecule owned by Viracta Therapeutics, and is involved in 5 clinical trials, of which 2 were completed, and 3 are ongoing.
Nanatinostat (VRx-3996) is a second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential anti-neoplastic activity. CHR-3996 is a class I HDAC selective inhibitor. This inhibition results an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent upregulate HSP70 and down-regulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors.
The revenue for Nanatinostat is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Nanatinostat NPV Report.
Nanatinostat (VRx-3996) is under development for the treatment for EBV-associated cancers including solid tumors like nasopharyngeal carcinoma, plasmablastic lymphoma, gastric cancer, nasopharyngeal cancer, colon cancer, natural killer cell lymphomas, peripheral T-cell lymphomas (PTCL), gastric carcinoma, leiomyosarcoma, sarcoma, angioimmunoblastic T-cell lymphoma, post-transplant lymphoproliferative disorder, cutaneous T cell lymphoma, diffuse large B cell lymphoma, systemic lupus erythematosus, latent viral infections and Hodgkin lymphoma. It is a small molecule administered orally. The drug is developed based on Esterase Sensitive Motif (ESM) technology.
It was also under development for the treatment of solid tumor and relapsed/refractory multiple myeloma.
Viracta Therapeutics Overview
Viracta Therapeutics, develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s pipeline products include Vecabrutinib (SNS-062) for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of pipeline products. Viracta is headquartered in Cardiff, California, the US.
The operating loss of the company was US$114 million in FY2021, compared to an operating loss of US$22.3 million in FY2020. The net loss of the company was US$114.8 million in FY2021, compared to a net loss of US$21.6 million in FY2020.
Quick View – Nanatinostat
|Highest Development Stage|